Found: 47
Select item for more details and to access through your institution.
Synthesis, radiofluorination, and preliminary evaluation of the potential 5-HT<sub>2A</sub> receptor agonists [<sup>18</sup>F]Cimbi-92 and [<sup>18</sup>F]Cimbi-150.
- Published in:
- Journal of Labelled Compounds & Radiopharmaceuticals, 2017, v. 60, n. 12, p. 586, doi. 10.1002/jlcr.3557
- By:
- Publication type:
- Article
Eptinezumab administered intravenously, subcutaneously, or intramuscularly in healthy subjects and/or patients with migraine: Early development studies.
- Published in:
- Cephalalgia Reports, 2022, v. 5, p. 1, doi. 10.1177/25158163221131326
- By:
- Publication type:
- Article
Fenfluramine Reduces [<sup>11</sup>C]Cimbi-36 Binding to the 5-HT<sub>2A</sub> Receptor in the Nonhuman Primate Brain.
- Published in:
- International Journal of Neuropsychopharmacology, 2017, v. 20, n. 9, p. 683, doi. 10.1093/ijnp/pyx051
- By:
- Publication type:
- Article
Blood BDNF concentrations reflect brain-tissue BDNF levels across species.
- Published in:
- International Journal of Neuropsychopharmacology, 2011, v. 14, n. 3, p. 347, doi. 10.1017/S1461145710000738
- By:
- Publication type:
- Article
Plaque deposition dependent decrease in 5-HT2A serotonin receptor in AbetaPPswe/PS1dE9 amyloid overexpressing mice.
- Published in:
- 2010
- By:
- Publication type:
- journal article
Shift in diagnostic classification of migraine after initiation of preventive treatment with eptinezumab: post hoc analysis of the PROMISE studies.
- Published in:
- BMC Neurology, 2022, v. 22, n. 1, p. 1, doi. 10.1186/s12883-022-02914-9
- By:
- Publication type:
- Article
Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumab.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Design of Infusion Schemes for Neuroreceptor Imaging: Application to [11C]Flumazenil-PET Steady-State Study.
- Published in:
- BioMed Research International, 2016, v. 2016, p. 1, doi. 10.1155/2016/9132840
- By:
- Publication type:
- Article
Patient Expectations and Experiences of Antidepressant Therapy for Major Depressive Disorder: A Qualitative Study.
- Published in:
- Neuropsychiatric Disease & Treatment, 2021, v. 17, p. 2995, doi. 10.2147/NDT.S325954
- By:
- Publication type:
- Article
Real-world effectiveness of vortioxetine in outpatients with major depressive disorder: functioning and dose effects.
- Published in:
- BMC Psychiatry, 2022, v. 22, n. 1, p. 1, doi. 10.1186/s12888-022-04109-5
- By:
- Publication type:
- Article
Cognitive Performance of Göttingen Minipigs Is Affected by Diet in a Spatial Hole-Board Discrimination Test.
- Published in:
- PLoS ONE, 2013, v. 8, n. 11, p. 1, doi. 10.1371/journal.pone.0079429
- By:
- Publication type:
- Article
An approach for serotonin depletion in pigs: Effects on serotonin receptor binding.
- Published in:
- Synapse, 2011, v. 65, n. 2, p. 136, doi. 10.1002/syn.20827
- By:
- Publication type:
- Article
Cerebral 5-HT release correlates with [<sup>11</sup>C]Cimbi36 PET measures of 5-HT2A receptor occupancy in the pig brain.
- Published in:
- Journal of Cerebral Blood Flow & Metabolism, 2017, v. 37, n. 2, p. 425, doi. 10.1177/0271678X16629483
- By:
- Publication type:
- Article
Serotonin 2A receptor agonist binding in the human brain with [<sup>11</sup>C]Cimbi-36.
- Published in:
- Journal of Cerebral Blood Flow & Metabolism, 2014, v. 34, n. 7, p. 1188, doi. 10.1038/jcbfm.2014.68
- By:
- Publication type:
- Article
Long-term effectiveness of eptinezumab in patients with migraine and prior preventive treatment failures: extension of a randomized controlled trial.
- Published in:
- Journal of Headache & Pain, 2023, v. 24, n. 1, p. 1, doi. 10.1186/s10194-023-01688-w
- By:
- Publication type:
- Article
Effects of eptinezumab on self-reported work productivity in adults with migraine and prior preventive treatment failure in the randomized, double-blind, placebo-controlled DELIVER study.
- Published in:
- Journal of Headache & Pain, 2022, v. 23, n. 1, p. 1, doi. 10.1186/s10194-022-01521-w
- By:
- Publication type:
- Article
Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study.
- Published in:
- Journal of Headache & Pain, 2022, v. 23, n. 1, p. 1, doi. 10.1186/s10194-021-01376-7
- By:
- Publication type:
- Article
Measuring endogenous changes in serotonergic neurotransmission with [<sup>11</sup>C]Cimbi-36 positron emission tomography in humans.
- Published in:
- Translational Psychiatry, 2019, v. 9, n. 1, p. N.PAG, doi. 10.1038/s41398-019-0468-8
- By:
- Publication type:
- Article
Radiosynthesis and in vivo evaluation of a series of substituted C-phenethylamines as 5-HT agonist PET tracers.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2011, v. 38, n. 4, p. 681, doi. 10.1007/s00259-010-1686-8
- By:
- Publication type:
- Article
Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study.
- Published in:
- Cephalalgia, 2023, v. 43, n. 5, p. 1, doi. 10.1177/03331024231170807
- By:
- Publication type:
- Article
Reduction in migraine-associated burden after eptinezumab treatment in patients with chronic migraine.
- Published in:
- Cephalalgia, 2022, v. 42, n. 10, p. 1005, doi. 10.1177/03331024221089567
- By:
- Publication type:
- Article
Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2.
- Published in:
- Cephalalgia, 2022, v. 42, n. 8, p. 696, doi. 10.1177/03331024221077646
- By:
- Publication type:
- Article
Similar serotonin-2A receptor binding in rats with different coping styles or levels of aggression.
- Published in:
- Synapse, 2015, v. 69, n. 4, p. 226, doi. 10.1002/syn.21810
- By:
- Publication type:
- Article
Acute social defeat does not alter cerebral 5-HT<sub>2A</sub> receptor binding in male Wistar rats.
- Published in:
- Synapse, 2014, v. 68, n. 9, p. 379, doi. 10.1002/syn.21750
- By:
- Publication type:
- Article
Direct comparison of [<sup>18</sup>F]MH.MZ and [<sup>18</sup>F]altanserin for 5-HT<sub>2A</sub> receptor imaging with PET.
- Published in:
- Synapse, 2013, v. 67, n. 6, p. 328, doi. 10.1002/syn.21643
- By:
- Publication type:
- Article
No change in [<sup>11</sup>C]CUMI-101 binding to 5-HT<sub>1A</sub> receptors after intravenous citalopram in human.
- Published in:
- Synapse, 2012, v. 66, n. 10, p. 880, doi. 10.1002/syn.21579
- By:
- Publication type:
- Article
Radiosynthesis and In Vivo Evaluation of Novel Radioligands for PET Imaging of Cerebral 5-HT<sub>7</sub> Receptors.
- Published in:
- Journal of Nuclear Medicine, 2014, v. 55, n. 4, p. 640, doi. 10.2967/jnumed.113.128983
- By:
- Publication type:
- Article
<sup>11</sup>C-NS14492 as a Novel PET Radioligand for Imaging Cerebral α7 Nicotinic Acetylcholine Receptors: In Vivo Evaluation and Drug Occupancy Measurements.
- Published in:
- Journal of Nuclear Medicine, 2011, v. 52, n. 9, p. 1449, doi. 10.2967/jnumed.111.088815
- By:
- Publication type:
- Article
Radiosynthesis and Evaluation of <sup>11</sup>C-CIMBI-5 as a 5-HT<sup>2A</sup> Receptor Agonist Radioligand for PET.
- Published in:
- Journal of Nuclear Medicine, 2010, v. 51, n. 11, p. 1763, doi. 10.2967/jnumed.109.074021
- By:
- Publication type:
- Article
Pharmacokinetics and Safety of Eptinezumab in Healthy Chinese Participants: A Randomized Clinical Trial.
- Published in:
- Clinical Drug Investigation, 2023, v. 43, n. 11, p. 873, doi. 10.1007/s40261-023-01315-1
- By:
- Publication type:
- Article
Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical Trial.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Eptinezumab for migraine prevention in patients 50 years or older.
- Published in:
- Acta Neurologica Scandinavica, 2022, v. 145, n. 6, p. 698, doi. 10.1111/ane.13603
- By:
- Publication type:
- Article
Responder rates with eptinezumab over 24 weeks in patients with prior preventive migraine treatment failures: post hoc analysis of the DELIVER randomized clinical trial.
- Published in:
- European Journal of Neurology, 2024, v. 31, n. 2, p. 1, doi. 10.1111/ene.16131
- By:
- Publication type:
- Article
Eptinezumab improved patient‐reported outcomes and quality of life in patients with migraine and prior preventive treatment failures.
- Published in:
- European Journal of Neurology, 2023, v. 30, n. 4, p. 1089, doi. 10.1111/ene.15670
- By:
- Publication type:
- Article
Evaluating the clinical utility of the patient‐identified most bothersome symptom measure from PROMISE‐2 for research in migraine prevention.
- Published in:
- Headache: The Journal of Head & Face Pain, 2022, v. 62, n. 6, p. 690, doi. 10.1111/head.14295
- By:
- Publication type:
- Article
Efficacy and safety of eptinezumab in patients with chronic migraine and medication-overuse headache: a randomized, double-blind, placebo-controlled study.
- Published in:
- BMC Neurology, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12883-023-03477-z
- By:
- Publication type:
- Article
Correction: Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Pharmacokinetics and Safety of Vortioxetine in the Chinese Population.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies.
- Published in:
- Journal of Headache & Pain, 2021, v. 22, n. 1, p. 1, doi. 10.1186/s10194-021-01360-1
- By:
- Publication type:
- Article
Preclinical safety assessment of the 5-HT2A receptor agonist PET radioligand [ 11C]Cimbi-36.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Preclinical Safety Assessment of the 5-HT Receptor Agonist PET Radioligand [C]Cimbi-36.
- Published in:
- Molecular Imaging & Biology, 2013, v. 15, n. 4, p. 376, doi. 10.1007/s11307-012-0609-4
- By:
- Publication type:
- Article
Cerebral Markers of the Serotonergic System in Rat Models of Obesity and After Roux-en-Y Gastric Bypass.
- Published in:
- Obesity (19307381), 2012, v. 20, n. 10, p. 2133, doi. 10.1038/oby.2012.75
- By:
- Publication type:
- Article
Patient-reported depression severity and cognitive symptoms as determinants of functioning in patients with major depressive disorder: a secondary analysis of the 2-year prospective PERFORM study.
- Published in:
- Neuropsychiatric Disease & Treatment, 2019, v. 15, p. 2313, doi. 10.2147/NDT.S206825
- By:
- Publication type:
- Article
Cognitive symptoms in major depressive disorder: associations with clinical and functional outcomes in a 6-month, non-interventional, prospective study in China.
- Published in:
- Neuropsychiatric Disease & Treatment, 2019, v. 15, p. 1723, doi. 10.2147/NDT.S195505
- By:
- Publication type:
- Article
Relationship between response to aripiprazole once-monthly and paliperidone palmitate on work readiness and functioning in schizophrenia: A post-hoc analysis of the QUALIFY study.
- Published in:
- PLoS ONE, 2017, v. 12, n. 8, p. 1, doi. 10.1371/journal.pone.0183475
- By:
- Publication type:
- Article
Vortioxetine for attention deficit hyperactivity disorder in adults: A randomized, double-blind, placebo-controlled, proof-of-concept study.
- Published in:
- 2019
- By:
- Publication type:
- journal article